William Blair analyst Matt Phipps has reiterated their bullish stance on AUTL stock, giving a Buy rating on November 3.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Phipps has given his Buy rating due to a combination of factors including the promising start of Autolus Therapeutics’ product, Aucatzyl, despite some initial challenges. The third-quarter sales were slightly below expectations, but deferred revenue and the impact of CMS reimbursement changes suggest a strong underlying momentum.
Despite the temporary setbacks, the company’s strategy to expand authorized treatment centers and the strong enthusiasm from physicians are expected to drive future growth. The potential market expansion into areas like pediatric ALL and lupus nephritis, coupled with Aucatzyl’s unique safety and efficacy profile, positions the product for a significant market opportunity. These factors underpin the confidence in Autolus’s future performance, justifying the Buy rating.
In another report released on November 3, Needham also maintained a Buy rating on the stock with a $10.00 price target.